News
Bausch + Lomb buys US rights to Stada's Lucentis biosimilar
Bausch + Lomb has bought US and Canadian rights to a potential biosimilar competitor to Novartis’ Lucentis from Germany’s Stada, as the blockbuster approaches the end of its patent protecte